China's Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million deal Reuters
China's Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million deal
China's Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million deal Reuters
Key Takeaways
- China's Qyuns Therapeutics licenses antibody program to Caldera in up to $780 million deal.
Read Complete Original Article
Published originally on Reuters





